Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics, Inc. furnished a Regulation FD disclosure on September 3, 2025 indicating the company has posted a corporate presentation to its website for use in investor meetings. The presentation is furnished as Exhibit 99.1 and is incorporated by reference into this report. The filing states the presentation may be used in meetings with investors and clarifies that, except where expressly referenced, the presentation will not be deemed incorporated by reference into other securities filings. The report is signed by Matthew Korenberg, Chief Financial Officer.
Palvella Therapeutics, Inc. (PVLA) disclosed a Schedule 13G/A reporting that Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju together beneficially own 339,743 shares of common stock, representing 3.1% of the class based on 11,055,665 shares outstanding as of May 9, 2025. The filing states Samsara LP directly holds the shares, Samsara GP is the general partner and Dr. Akkaraju is a managing member, and that the holdings were not acquired to change or influence control of the issuer.
The filing is dated for the reporting event as of June 30, 2025 and signatures show execution on August 14, 2025. The reporting address is c/o Samsara BioCapital, LLC, Palo Alto, CA.
Frazier Life Sciences and affiliated funds report their holdings in Palvella Therapeutics, Inc. common stock. Frazier Life Sciences Public Fund, L.P. (FLSPF) directly holds 545,504 shares, which the filing states represents 4.9% of the 11,055,665 shares of common stock used for the percentage calculation. Other Frazier vehicles reported include holdings of 160,856, 7,517, 4,730 and 3,793 shares, with sole voting and dispositive power reported as 0 and shared power reported where indicated.
The filing corrects prior attributions by stating members of certain investment committees are not attributed beneficial ownership of fund-held securities. It also discloses prefunded warrants: FLSPF holds warrants to purchase 937,965 shares, FLSPOF 276,766, FLS X 5,641 and FLS XI 5,886, each subject to exercise limits preventing the holder from exceeding 4.99% beneficial ownership after exercise. The statement clarifies ownership, voting and dispositive arrangements among the reporting persons.
Palvella Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on topical QTORIN rapamycin for rare genetic skin diseases. At June 30, 2025 the company held $70.4 million in cash and cash equivalents, total assets of $73.7 million and an accumulated deficit of $111.4 million. For the six months ended June 30, 2025 Palvella reported a net loss of $17.7 million driven by total operating expenses of $17.1 million (R&D and G&A).
The company completed a reverse merger and related PIPE financing that provided substantial capital; management states existing cash is sufficient to support operations through at least one year from issuance of these statements assuming no additional fundraising. Key balance sheet items include a $14.5 million royalty agreement liability and Level 3 derivative liabilities for the royalty agreement and contingent value rights totaling $3.8 million. Clinical progress includes completion of enrollment in the Phase 3 SELVA trial (51 subjects), dosing in the Phase 2 TOIVA trial, receipt of an initial $0.5 million FDA grant, and a newly granted U.S. patent for anhydrous rapamycin formulations.
Palvella Therapeutics, Inc. reported that on August 14, 2025 it announced financial results for the quarter ended June 30, 2025. The company furnished a press release and an earnings-call slide presentation as Exhibits 99.1 and 99.2 to this Current Report, and will hold an earnings call using the presentation on the same date. The filing explicitly states that the materials are being furnished rather than "filed," so they are not subject to the liabilities of Section 18 of the Exchange Act and are not automatically incorporated by reference into other SEC filings.
The report provides notice of the release and the investor presentation but does not include financial figures, results detail, or forward-looking guidance within the 8-K text itself; investors must consult the furnished press release and presentation for substantive financial information.